Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Cancer Treatment Center of America, Philadelphia, Pennsylvania, United States
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
PRA International, Raleigh, North Carolina, United States
PRA, Intl., Raleigh, North Carolina, United States
Nemazee Hospital, Shiraz, Fars, Iran, Islamic Republic of
Providence Hospital and Medical Center, Southfield, Michigan, United States
Department of Anaesthesiology, University Hospital Örebro, Örebro, Sweden
University Hospital Örebro, Örebro, Sweden
Fletcher Allen Health Care, Burlington, Vermont, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.